Aaron Boster from OhioHealth: Extended Data On Lemtrada Shows More Good News

Video

As more and more treatments are approved for patients with multiple sclerosis questions are being answered about their effectiveness long past their approval dates. This is true for many of the medications including lemtrada.

As more and more treatments are approved for patients with multiple sclerosis questions are being answered about their effectiveness long past their approval dates. This is true for many of the medications including Lemtrada.

Aaron Boster, MD, from OhioHealth discussed the latest data being presented on the medication at the annual ECTRIMS conference in London. Unlike other treatments which are taken daily, weekly, or monthly Boster noted Lemtrada is given in much more extended durations and has shown to be effective for much longer periods of time. Many patients, he noted, do not need any further treatment after a second dose of the medication.

Related Videos
HCPLive Five at ACC 2024 | Image Credit: HCPLive
Ankeet Bhatt, MD, MBA | Credit: X.com
Ankeet Bhatt, MD, MBA | Credit: X.com
Sara Saberi, MD | Credit: University of Michigan
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Veraprapas Kittipibul, MD | Credit: X.com
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA
© 2024 MJH Life Sciences

All rights reserved.